DexCom, Inc. $DXCM Shares Acquired by Gradient Investments LLC

Key Points

• Gradient Investments LLC increased its stake in DexCom by 13.8%, adding 40,343 shares to hold 332,006 shares valued at about $22.0 million, while institutional investors now own roughly 97.75% of the company.
• DexCom topped expectations in its latest quarter with $0.68 EPS vs. $0.65 expected and $1.26 billion in revenue, up 13.1% year-over-year, with a net margin of 17.94% and ROE of 32.12%.
• Analysts are broadly positive: MarketBeat reports a consensus rating of "Moderate Buy" and an average price target of $85.50, with individual targets ranging roughly $68–$95.

Gradient Investments LLC boosted its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 13.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 332,006 shares of the medical device company's stock after purchasing an additional 40,343 shares during the period. Gradient Investments LLC owned about 0.09% of DexCom worth $22,035,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the business. Twin Peaks Wealth Advisors LLC acquired a new position in shares of DexCom in the 2nd quarter valued at approximately $26,000. SJS Investment Consulting Inc. grew its position in shares of DexCom by 4,800.0% during the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company's stock worth $26,000 after buying an additional 384 shares in the last quarter. Financial Consulate Inc. acquired a new stake in shares of DexCom during the third quarter worth approximately $29,000. Sound Income Strategies LLC increased its stake in shares of DexCom by 83.8% in the third quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company's stock worth $43,000 after buying an additional 285 shares during the last quarter. Finally, Aventura Private Wealth LLC bought a new stake in shares of DexCom in the fourth quarter worth $43,000. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Stock Performance

DexCom stock opened at $66.95 on Monday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The company has a fifty day moving average price of $70.50 and a two-hundred day moving average price of $68.03. The company has a market cap of $25.77 billion, a PE ratio of 31.88, a P/E/G ratio of 1.30 and a beta of 1.48.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, topping analysts' consensus estimates of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The company had revenue of $1.26 billion for the quarter, compared to analysts' expectations of $1.25 billion. During the same period in the prior year, the company earned $0.45 earnings per share. The firm's revenue was up 13.1% compared to the same quarter last year. Research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have commented on DXCM. Weiss Ratings upgraded shares of DexCom from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, March 4th. Evercore began coverage on shares of DexCom in a research report on Tuesday, November 25th. They issued an "in-line" rating and a $68.00 target price for the company. Canaccord Genuity Group set a $95.00 target price on shares of DexCom and gave the company a "buy" rating in a research note on Friday, February 13th. Truist Financial reaffirmed a "buy" rating and set a $80.00 price target (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Finally, Robert W. Baird set a $87.00 price target on DexCom in a research note on Friday, February 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, DexCom presently has an average rating of "Moderate Buy" and a consensus price target of $85.50.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the firm's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $64.85, for a total value of $110,245.00. Following the transaction, the executive vice president owned 112,904 shares of the company's stock, valued at $7,321,824.40. This trade represents a 1.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.32% of the stock is currently owned by company insiders.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.